A study by Coudray et al. (2018) [101] showed an impressive accuracy in predicting molecular phenotype, ranging from 73% to 85.6% for EGFR and KRAS mutations, two of the most important targetable pathways in NSCLC, making a profound impact on personalized treatment strategies. This evidence concerns the gene KRAS and non-small cell lung carcinoma.